U.S. FDA Accepts AbbVie ' s New Drug Application for Atogepant for the Preventive Treatment of Migraine

NORTH CHICAGO, Ill., March 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for atogepant, an investigational orally administered...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news